Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

5,180 studies for “Merck”

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Recruiting
NCT06395103Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma
United States, Australia, Belgium, Brazil, Canada +18 more
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Recruiting
NCT07519772Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse
United States, Argentina, China, Israel, Italy +4 more
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)Recruiting
NCT06818643Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Tumors · Malignant Neoplasm
United States, Chile, China, France, Israel +7 more
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)Active Not Recruiting
NCT03765918Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Head and Neck Neoplasms
United States, Argentina, Australia, Austria, Belgium +19 more
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)Recruiting
NCT07600749Phase 1Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Israel, Japan, Switzerland
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Recruiting
NCT06623422Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +26 more
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Recruiting
NCT07405164Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Von Hippel-Lindau Disease · Malignant Neoplasms
United States, Australia, Belgium, Brazil, Canada +17 more
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting
NCT06966700Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +34 more
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Recruiting
NCT07513376Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Australia, Canada, Germany, Greece +8 more
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Recruiting
NCT06824467Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
United States, Argentina, Australia, Belgium, Brazil +23 more
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)Recruiting
NCT06952504Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Cancer
United States, Argentina, Australia, Austria, Belgium +29 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Recruiting
NCT07570173Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia
Denmark, Israel, Italy, Japan, Netherlands +1 more
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Recruiting
NCT07634471Phase 2, Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Follicular Lymphoma
United States, Israel, Spain, Taiwan, Turkey (Türkiye)
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's DiseaseTerminated
NCT07348250EARLY_Phase 1Updated Jul 27, 2026
Sponsor: Invicro
Parkinson's Disease (PD) · Parkinson's Disease · Parkinson's Disease (Disorder)
United States
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Recruiting
NCT07318558Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Neoplasms · Ovarian Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)Recruiting
NCT06843447Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer Recurrent
United States, Canada, Israel, Spain, United Kingdom
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Recruiting
NCT07489495Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States, Argentina, Australia, Brazil, Czechia +12 more
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +29 more
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Recruiting
NCT07227402Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Renal Cell Carcinoma
United States, Argentina, Australia, Austria, Belgium +17 more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Recruiting
NCT07216703Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Austria, Belgium, Brazil +22 more
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Recruiting
NCT07419295Phase 3Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Argentina, Australia, Belgium, Brazil +11 more
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot Yet Recruiting
NCT07094893Phase 4Updated Jul 24, 2026
Sponsor: Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Recruiting
NCT05947851Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell Lymphoma · Lymphoma, Small Lymphocytic
United States, Argentina, Australia, Belgium, Brazil +13 more

5,180 studies found